MedTrace Logo

Organic Cation Transporter 1 (OCT1), on Response to Metformin in Healthy Subjects

NCT00187681 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2013-01-08

Study results available
· View outcomes & findings →

Summary

Specific Objectives:

* To determine if individuals who carry a decreased or non-functional variant of OCT1 exhibit differences in the pharmacokinetics of metformin in comparison to individuals who carry the common allele.
* To determine if individuals who carry the decreased or non-functional variants exhibit differences in the response to metformin in comparison to individuals who carry the common allele.

Conditions

  • Other Conditions That May Be A Focus of Clinical Attention

Interventions

DRUG

Metformin

2 doses of Metformin Day 1 1000mg, Day 2 850 mg

Sponsors & Collaborators

Principal Investigators

  • Kathleen M Giacomini, PhD · University of California, San Francisco

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2003-07-31
Primary Completion
2008-03-31
Completion
2008-03-31

Countries

  • United States

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00187681 on ClinicalTrials.gov